Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
References
1. C. DeBoer, et al.; J. Antibiot. 23: 442 (1970).|2. Inhibition of c-myc gene expression in murine lymphoblastoma cells by geldanamycin and herbimycin, antibiotics of benzoquinoid ansamycin group: H. Yamaki, et al.; J. Antibiot. 42: 604 (1989)|3. Geldanamycin selectively destabilizes and conformationally alters mutated p53: M.V. Blagosklonny, et al.; Oncogene 11: 933 (1995).|4. R.C. Schnur, et al.; J. Med. Chem. 38:3806 (1995).|5. L. Whitesell & P. Cook; Mol. Endocrinol. 10: 705 (1996).|6. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity: L. Neckers, et al.; Invest. New Drugs 17: 361 (1999), (Review).|7. Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs: M.V. Blagosklonny; Leukemia 16: 455 (2002), (Review).|8. Geldanamycin enhances hepatocyte growth factor stimulation of eNOS phosphorylation in endothelial cells: K. Makondo, et al.; Eur. J. Pharmacol. 582: 110 (2007)|9. HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells in vitro and seeding into bone marrow in vivo: E. Lesko, et al.; Anticancer Drugs 18: 1173 (2007).|10. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo: S.A. Lang, et al.; Mol. Cancer Ther. 6: 1123 (2007).|11. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells: F. Koga, et al.; Cell Cycle 6: 1393 (2007).|12. K. Sugimoto, et al.; Oncogene 27: 3091 (2008)USBio References
No references available